未接受(新)辅助全身治疗的年轻、淋巴结阴性三阴性乳腺癌患者中基质肿瘤浸润淋巴细胞的预后价值
该研究从荷兰人群登记库选取1989至2000年诊断的441例年龄<40岁、淋巴结阴性、未接受(新)辅助全身治疗的三阴性乳腺癌患者,评估基质肿瘤浸润淋巴细胞(sTILs)的预后价值。结果显示sTILs≥75%者15年远处转移或死亡累积发生率仅2.1%,而<30%者为38.4%;sTILs每增加10%死亡风险降低19%(校正HR 0.81,95%CI 0.76-0.87),为独立预后因素。作者认为高sTILs患者预后极佳,应考虑在前瞻性临床试验中研究化疗降阶梯策略。
要点
- 年轻、淋巴结阴性、未接受化疗的三阴性乳腺癌患者中,sTILs≥75%者15年远处转移或死亡累积发生率仅2.1%。
- sTILs<30%者15年远处转移或死亡累积发生率为38.4%。
- sTILs每增加10%,死亡风险降低19%(校正HR 0.81,95%CI 0.76-0.87),为独立预后因素。
核心结论
- 未接受化疗的年轻、淋巴结阴性三阴性乳腺癌患者中,sTILs≥75%者具有极佳的长期预后。
- 作者认为应考虑在前瞻性临床试验中研究基于sTILs的(新)辅助化疗降阶梯策略。
研究设计与样本
- 从荷兰人群登记库选取1989至2000年诊断的淋巴结阴性三阴性乳腺癌患者,诊断时年龄<40岁且未接受(新)辅助全身治疗(当时标准实践)。
- 调取福尔马林固定石蜡包埋组织块(PALGA:荷兰病理登记库),进行包括sTILs评估的病理复审。
- 共441例患者完成sTILs评分,按sTILs<30%、30%-75%、≥75%分组。
- 采用多变量Cox回归分析总生存,竞争风险模型分析远处转移或死亡的累积发生率,以第二原发肿瘤为竞争风险。
主要发现
- sTILs≥75%者(21%)15年远处转移或死亡累积发生率为2.1%(95%CI 0-5.0)。
- sTILs<30%者(52%)15年远处转移或死亡累积发生率为38.4%(95%CI 32.1-44.6)。
- sTILs每增加10%,死亡风险降低19%(校正HR 0.81,95%CI 0.76-0.87)。
- sTILs为独立预后因素,在标准临床病理变量基础上增加预后信息(χ2=46.7,P<.001)。
临床怎么用
- 作者认为,对于未接受化疗的年轻、淋巴结阴性三阴性乳腺癌患者,高sTILs(≥75%)预示极佳长期预后。
- 作者建议在前瞻性临床试验中考虑评估sTILs用于(新)辅助化疗降阶梯策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Triple-negative breast cancer (TNBC) is considered aggressive, and therefore, virtually all young patients with TNBC receive (neo)adjuvant chemotherapy. Increased stromal tumor-infiltrating lymphocytes (sTILs) have been associated with a favorable prognosis in TNBC. However, whether this association holds for patients who are node-negative (N0), young (< 40 years), and chemotherapy-naïve, and thus can be used for chemotherapy de-escalation strategies, is unknown. METHODS: We selected all patients with N0 TNBC diagnosed between 1989 and 2000 from a Dutch population-based registry. Patients were age < 40 years at diagnosis and had not received (neo)adjuvant systemic therapy, as was standard practice at the time. Formalin-fixed paraffin-embedded blocks were retrieved (PALGA: Dutch Pathology Registry), and a pathology review including sTILs was performed. Patients were categorized according to sTILs (< 30%, 30%-75%, and ≥ 75%). Multivariable Cox regression was performed for overall survival, with or without sTILs as a covariate. Cumulative incidence of distant metastasis or death was analyzed in a competing risk model, with second primary tumors as competing risk. RESULTS: sTILs were scored for 441 patients. High sTILs (≥ 75%; 21%) translated into an excellent prognosis with a 15-year cumulative incidence of a distant metastasis or death of only 2.1% (95% CI, 0 to 5.0), whereas low sTILs (< 30%; 52%) had an unfavorable prognosis with a 15-year cumulative incidence of a distant metastasis or death of 38.4% (32.1 to 44.6). In addition, every 10% increment of sTILs decreased the risk of death by 19% (adjusted hazard ratio: 0.81; 95% CI, 0.76 to 0.87), which are an independent predictor adding prognostic information to standard clinicopathologic variables (χ2 = 46.7, P < .001). CONCLUSION: Chemotherapy-naïve, young patients with N0 TNBC with high sTILs (≥ 75%) have an excellent long-term prognosis. Therefore, sTILs should be considered for prospective clinical trials investigating (neo)adjuvant chemotherapy de-escalation strategies.
引用
- de Jong VMT, Wang Y, Ter Hoeve ND, et al. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. J Clin Oncol. 2022. PMID: 35353548. doi:10.1200/JCO.21.01536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。